FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents an anticancer chemotherapeutic agent containing a combination of a cholestanol derivative presented by the formula
,
wherein G represents GlcNAc-Gal- or GlcNAc-, or its cyclodextrin inclusion compound, and irinotecan.
EFFECT: anticancer chemotherapeutic agent has excellent efficacy and fewer side effects.
7 cl, 6 ex, 9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED USE OF CHOLESTANOL DERIVATIVES | 2009 |
|
RU2492865C2 |
| THERAPEUTIC USE OF THE TLR AGONIST AND COMBINED THERAPY | 2011 |
|
RU2603467C2 |
| ANTITUMOUR MEDICATION | 2006 |
|
RU2410389C2 |
| PHARMACEUTICAL COMPOSITIONS, COMPOUNDS, METHODS OF SYNTHESIS OF COMPOUNDS | 1995 |
|
RU2168995C2 |
| PURIFIED DERIVATIVE OF CYCLODEXTRINE, CLATHRATE COMPLEX OF PURIFIED DERIVATIVE OF CYCLODEXTRINE WITH DRUG, PHARMACEUTICAL COMPOSITION | 1992 |
|
RU2099354C1 |
| COMBINATIONS FOR CANCER TREATMENT INCLUDING ABX196 | 2017 |
|
RU2770432C2 |
| PHOSPHORAMIDATE ALKYLATOR PRODRUG | 2006 |
|
RU2414475C2 |
| MODULAR PARTICLES FOR IMMUNOTHERAPY | 2014 |
|
RU2672055C2 |
| ON01910NA ENHANCING ACTIVITY OF CHEMOTHERAPEUTIC AGENT IN DRUG-RESISTANT TUMOURS | 2008 |
|
RU2476239C2 |
| NEW SYNERGETIC EFFECTS | 2009 |
|
RU2471499C2 |
